About Rivermark
Rivermark is a Healthcare company based in Milwaukee (United States) founded in 2021 by Andy Doraiswamy. Medical device for benign prostatic hyperplasia treatment is developed. Rivermark has raised $54.16 million across 3 funding rounds from investors including American Century Investments, Venture Investors and Time BioVentures. Its chief executive, as recorded, is Adam Kadlec. Rivermark offers products and services including FloStent. Its focus areas include Life Sciences, Genitourinary Disorders, Medical Devices and Therapeutics. Its legal entity is Rivermark Medical, Inc. Its competitors include Neotract, Zenflow and Urotronic; 3 of its 3 listed competitors have raised funding.
Company details
Established in 2021 in Milwaukee, United States, the company operates in the medical device sector. Focus is placed on a minimally invasive solution called FloStent, which utilizes a nitinol stent to keep the prostatic urethra open. Normal urinary function is thereby restored for patients with benign prostatic hyperplasia. Leadership includes co-founder Andy Doraiswamy as chairman and Adam Kadlec as CEO.
- Headquarters Milwaukee, United States
- Founders Andy Doraiswamy
- SectorsHealthcare
- Email••••••••
- Website rivermarkmedical.com
- Social LinkedIn
- Legal Name Rivermark Medical, Inc.
- Total Equity Funding$54.16M (USD)
in 3 rounds
- Latest Funding Round$20M (USD), Series D
May 2026
- InvestorsAmerican Century Investments
& 6 more
Products & Services of Rivermark
Rivermark offers a comprehensive portfolio of products and services, including FloStent.
Device for BPH treatment to restore urinary flow quickly.
Funding Insights of Rivermark
Rivermark has successfully raised a total of $54.16M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $20 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $54.16M
- Total Rounds 3
- Last Round Series D — $20M
- First Round $4.12M
(Jul 2023)
- Investors Count 7
All 3 funding rounds of Rivermark with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $20M | Series D | – | Andera Partners | – |
| Sep 2024 | $30.04M | Series C | – | American Century Investments | |
| Jul 2023 | $4.12M | Series A | – | – | – |
7 investors in total: 7 institutional.
Investors in Rivermark
Rivermark has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include American Century Investments, Venture Investors and Time BioVentures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia | ventureinvestors.com | Madison, United States | ||
Venture capital firm focused on life science and healthcare sectors | timebioventures.com | California City, United States | ||
Early-stage medical and health technology investments are facilitated. | 2020 | view-ventures.com | ||
Healthcare venture capital investments are made by Cadence Healthcare Ventures. | cadencehcvc.com | Ross, United States | ||
| anderapartners.com | ||||
Diversified investment management firm | 1958 | americancentury.com | Kansas City, United States | |
Investor details for Rivermark
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rivermark
2 people are tracked at Rivermark (2 in leadership).
| Name | Role | Group |
|---|---|---|
Andy Doraiswamy | Co-Founder & Chairman | Leadership |
Adam Kadlec | CEO | Leadership |
Complete people profiles for Rivermark
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rivermark
3 dated milestones of Rivermark across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Rivermark is founded.
- Funding First funding round of $4.1M.
- Funding Latest funding round, Series D, of $20.0M.
Competitors of Rivermark
Rivermark has 3 listed competitors in our database, 3 of them funded. They include Neotract, Zenflow and Urotronic.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neotract.com | 2004 | Mountain View, United States | $137.96M | 119 | Minimally invasive devices in urology | |
| zenflow.com | 2014 | Palo Alto, United States | $48M | 25 | A device is developed to treat urinary obstruction from BPH. | |
| urotronic.com | 2015 | Plymouth, United States | $47.05M | 18 | Urethral stricture treatment devices are developed by Urotronic. |
Detailed competitors of Rivermark
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genitourinary Disorders
3 companies that operate in the same segment as Rivermark (Genitourinary Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rivermark
Complete news archive for Rivermark
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rivermark
Rivermark was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Rivermark is headquartered in Milwaukee, United States. It is registered at Milwaukee, Wisconsin, United States.
Adam Kadlec is the CEO of Rivermark, as recorded in our data.
Rivermark is a funded company, having raised a total of $54.16M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4.12M, raised on Jul 2023.
Established in 2021 in Milwaukee, United States, the company operates in the medical device sector. Focus is placed on a minimally invasive solution called FloStent, which utilizes a nitinol stent to keep the prostatic urethra open. Normal urinary function is thereby restored for patients with benign prostatic hyperplasia. Leadership includes co-founder Andy Doraiswamy as chairman and Adam Kadlec as CEO.
Rivermark offers FloStent.
Rivermark has 7 investors. Key investors include American Century Investments, Venture Investors, Time BioVentures, View Ventures, and Cadence Healthcare Ventures.
Rivermark operates through Rivermark Medical, Inc..